Literature DB >> 20431554

Personalizing medicine for cancer: the next decade.

Ernest C Borden1, Derek Raghavan.   

Abstract

An important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that target the results of genetic defects in selected patients with cancer has led to some important treatment advances, but there remain major challenges to realizing the full potential of genomic medicine in oncology.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20431554     DOI： 10.1038/nrd3168

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  4 in total

1.  An essay on rearranging the deck chairs: what's wrong with the cancer trials system?

Authors:  Derek Raghavan
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

2.  The FDA as a public health agency.

Authors:  Margaret A Hamburg; Joshua M Sharfstein
Journal:  N Engl J Med       Date:  2009-05-26       Impact factor: 91.245

3.  The many uses of cancer prediction tools.

Authors:  Michael W Kattan
Journal:  Semin Oncol       Date:  2010-02       Impact factor: 4.929

4.  Project Zero Delay: a process for accelerating the activation of cancer clinical trials.

Authors:  Razelle Kurzrock; Susan Pilat; Marcel Bartolazzi; Dwana Sanders; Jill Van Wart Hood; Stanley D Tucker; Kevin Webster; Michael A Mallamaci; Steven Strand; Eileen Babcock; Robert C Bast
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544
  4 in total
  5 in total

1.  Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer.

Authors:  Nicole M Kuderer; Kimberly A Burton; Sibel Blau; Francis Senecal; Vijayakrishna K Gadi; Stephanie Parker; Elisabeth Mahen; David Veenstra; Josh J Carlson; Gary H Lyman; C Anthony Blau
Journal:  JCO Precis Oncol       Date:  2017-08-16

Review 2.  Personalized cardiovascular medicine: concepts and methodological considerations.

Authors:  Henry Völzke; Carsten O Schmidt; Sebastian E Baumeister; Till Ittermann; Glenn Fung; Janina Krafczyk-Korth; Wolfgang Hoffmann; Matthias Schwab; Henriette E Meyer zu Schwabedissen; Marcus Dörr; Stephan B Felix; Wolfgang Lieb; Heyo K Kroemer
Journal:  Nat Rev Cardiol       Date:  2013-03-26       Impact factor: 32.419

3.  Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.

Authors:  Fiona A Miller; Robin Z Hayeems; Jessica P Bytautas; Philippe L Bedard; Scott Ernst; Hal Hirte; Sebastien Hotte; Amit Oza; Albiruni Razak; Stephen Welch; Eric Winquist; Janet Dancey; Lillian L Siu
Journal:  Eur J Hum Genet       Date:  2013-07-17       Impact factor: 4.246

4.  Personalized medicine and access to health care: potential for inequitable access?

Authors:  Kelly A McClellan; Denise Avard; Jacques Simard; Bartha M Knoppers
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

5.  A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.

Authors:  Shun-Ichi Suzuki; Satoshi Matsusaka; Mitsuharu Hirai; Harumi Shibata; Koichi Takagi; Nobuyuki Mizunuma; Kiyohiko Hatake
Journal:  Int J Oncol       Date:  2015-04-30       Impact factor: 5.650
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.